Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial.

[1]  Y. Clayton.  Relevance of broad‐spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses , 1994, The British journal of dermatology.

[2]  L. Millérioux,et al.  Levels of terbinafine in plasma, stratum corneum, dermis–epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days , 1994, Clinical and experimental dermatology.

[3]  E. Evans,et al.  Short term treatment of dermatophyte onychomycosis with terbinafine. , 1992, BMJ.

[4]  D. Back,et al.  Azoles, a48 llylamines and drug metabolism , 1992 .

[5]  T. Jones,et al.  Special features of the clinical use of oral terbinafine in the treatment of fungal diseases , 1992, The British journal of dermatology.

[6]  D. Roberts,et al.  Prevalence of dermatophyte onychomycosis in the United Kingdom: Results of an omnibus survey , 1992, The British journal of dermatology.

[7]  H. Korting,et al.  Is tinea unguium still widely incurable? A review three decades after the introduction of griseofulvin. , 1992, Archives of dermatology.

[8]  A. Finlay.  Pharmacokinetics of terbinafine in the nail. , 1992, The British journal of dermatology.

[9]  M. Crijns,et al.  A randomized treatment duration‐finding study of terbinafine in onychomycosis , 1992, The British journal of dermatology.

[10]  N. Ryder.  The mechanism of action of terbinafine , 1989, Clinical and experimental dermatology.

[11]  N. Zaias,et al.  The successful treatment of finger Trichophyton rubrum onychomycosis with oral terbinafine , 1989, Clinical and experimental dermatology.

[12]  R. Hay,et al.  A comparative double blind study of ketoconazole and griseofulvin in dermatophytosis , 1985, The British journal of dermatology.

[13]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.